258 related articles for article (PubMed ID: 19777160)
1. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
Roy Choudhury S; Karmakar S; Banik NL; Ray SK
Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 inhibitor HA14-1 and genistein together adeptly down regulated survival factors and activated cysteine proteases for apoptosis in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells.
Mohan N; Karmakar S; Choudhury SR; Banik NL; Ray SK
Brain Res; 2009 Aug; 1283():155-66. PubMed ID: 19505441
[TBL] [Abstract][Full Text] [Related]
3. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
4. Retinoids induce differentiation and downregulate telomerase activity and N-Myc to increase sensitivity to flavonoids for apoptosis in human malignant neuroblastoma SH-SY5Y cells.
Das A; Banik NL; Ray SK
Int J Oncol; 2009 Mar; 34(3):757-65. PubMed ID: 19212680
[TBL] [Abstract][Full Text] [Related]
5. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Dasmahapatra G; Yerram N; Dai Y; Dent P; Grant S
Clin Cancer Res; 2007 Jul; 13(14):4280-90. PubMed ID: 17634558
[TBL] [Abstract][Full Text] [Related]
6. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Liu Q; Mier JW; Panka DJ
Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
[TBL] [Abstract][Full Text] [Related]
7. Survivin knockdown increased anti-cancer effects of (-)-epigallocatechin-3-gallate in human malignant neuroblastoma SK-N-BE2 and SH-SY5Y cells.
Hossain MM; Banik NL; Ray SK
Exp Cell Res; 2012 Aug; 318(13):1597-610. PubMed ID: 22507272
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 inhibitor and apigenin worked synergistically in human malignant neuroblastoma cell lines and increased apoptosis with activation of extrinsic and intrinsic pathways.
Karmakar S; Davis KA; Choudhury SR; Deeconda A; Banik NL; Ray SK
Biochem Biophys Res Commun; 2009 Oct; 388(4):705-10. PubMed ID: 19695221
[TBL] [Abstract][Full Text] [Related]
9. Synergistic efficacy of a novel combination therapy controls growth of Bcl-x(L) bountiful neuroblastoma cells by increasing differentiation and apoptosis.
Mohan N; Banik NL; Ray SK
Cancer Biol Ther; 2011 Nov; 12(9):846-54. PubMed ID: 21878749
[TBL] [Abstract][Full Text] [Related]
10. The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.
Brüning A; Rahmeh M; Gingelmaier A; Friese K
Mol Cancer; 2010 Jan; 9():19. PubMed ID: 20105315
[TBL] [Abstract][Full Text] [Related]
11. N-Myc down regulation induced differentiation, early cell cycle exit, and apoptosis in human malignant neuroblastoma cells having wild type or mutant p53.
Janardhanan R; Banik NL; Ray SK
Biochem Pharmacol; 2009 Nov; 78(9):1105-14. PubMed ID: 19540207
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
[TBL] [Abstract][Full Text] [Related]
13. Genistein induces receptor and mitochondrial pathways and increases apoptosis during BCL-2 knockdown in human malignant neuroblastoma SK-N-DZ cells.
George J; Banik NL; Ray SK
J Neurosci Res; 2010 Mar; 88(4):877-86. PubMed ID: 19813266
[TBL] [Abstract][Full Text] [Related]
14. Synergistic activity of letrozole and sorafenib on breast cancer cells.
Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Huang S; Sinicrope FA
Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
[TBL] [Abstract][Full Text] [Related]
16. SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
Mohan N; Karmakar S; Banik NL; Ray SK
Neurochem Res; 2011 Aug; 36(8):1383-96. PubMed ID: 21472456
[TBL] [Abstract][Full Text] [Related]
17. N-Myc knockdown and apigenin treatment controlled growth of malignant neuroblastoma cells having N-Myc amplification.
Hossain MM; Banik NL; Ray SK
Gene; 2013 Oct; 529(1):27-36. PubMed ID: 23941992
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Oh SJ; Erb HH; Hobisch A; Santer FR; Culig Z
Endocr Relat Cancer; 2012 Jun; 19(3):305-19. PubMed ID: 22383427
[TBL] [Abstract][Full Text] [Related]
19. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.
Chai H; Luo AZ; Weerasinghe P; Brown RE
Int J Clin Exp Pathol; 2010 Apr; 3(4):408-15. PubMed ID: 20490331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
